The KDM5A Knockout HEK293T Polyclonal Cells product constitutes a CRISPR/Cas9-edited polyclonal cell population in which the KDM5A gene has been functionally disrupted. This gene-edited cell model is generated by introducing targeted disruptions into the endogenous KDM5A locus via CRISPR/Cas9 genome editing, resulting in a heterogeneous knockout pool. The polyclonal format offers a population-level knockout representation suitable for loss-of-function studies without clonal selection artifacts, making it ideal for applications that require genetic perturbation across a broad cellular background.
The cell model is derived from the HEK293T cell line, an adherent embryonic kidney epithelial cell line of human origin. HEK293T cells are a widely used derivative of the HEK293 line, stably expressing the SV40 large T antigen, which enhances episomal replication of plasmids containing the SV40 origin of replication and facilitates high-level protein expression. These characteristics make HEK293T a preferred host for transient transfection, stable protein production, lentiviral packaging, and various functional assays. The cells retain an epithelial morphology and grow as a monolayer, offering robust and reproducible culture conditions.
KDM5A encodes a histone H3 lysine 4 demethylase that specifically removes di- and trimethyl marks (H3K4me2/3), leading to transcriptional repression. The protein is recruited to chromatin through direct interactions with the retinoblastoma protein RB1, retinoic acid receptors RAR/RXR, or the intracellular domain of NOTCH1, and assembles into a corepressor complex that includes SIN3A, HDAC1, and HDAC2. Mechanistically, KDM5A dampens gene expression programs by demethylating H3K4 at target promoters, thereby counteracting active transcription. Key downstream targets subject to KDM5A-mediated silencing include CCND1, multiple HOXA cluster homeobox genes, MYC, BRCA1, and CDKN1A. Upstream regulation of KDM5A involves transcriptional control by E2F4, HOXA10, and integration into the RB1/E2F4/SIN3A/HDAC1 transcriptional repressor module, as well as signaling crosstalk with the RAR/RXR/HOXA and NOTCH1/HES1 axes.
In the context of HEK293T cells, which possess a transformed phenotype and express SV40 large T antigen that inactivates p53 and RB1, the loss of KDM5A provides a unique system to dissect RB1-independent functions of this demethylase. The model enables interrogation of KDM5A??s role in modulating cell cycle progression, retinoic acid-responsive differentiation, and Notch-dependent transcriptional programs. Moreover, because HEK293T cells are frequently used in cancer biology and epigenetics research, this knockout model serves as a tractable platform for investigating KDM5A-linked pathologies including Claes-Jensen syndrome (KDM5A-related intellectual disability), breast cancer, lung adenocarcinomas, and gastric cancer.
This polyclonal knockout cell population is amenable to a wide array of downstream analyses, including western blotting, RT-qPCR, ChIP-qPCR for assessing H3K4 methylation status, RNA-seq for transcriptome-wide profiling, histone demethylase biochemical activity assays, immunofluorescence to monitor protein localization, and drug sensitivity screens. Applications span cancer epigenetics research, drug target validation, mechanistic studies of histone demethylation, neurodevelopmental disorder modeling, and functional genomics screening. Researchers can use this model to evaluate the impact of KDM5A deficiency on cellular proliferation, differentiation, and therapeutic response. For further details, please contact Ascent Research.
